's () chief executive Richard Hullihen tells Proactive London's Andrew Scott the enrolment of the final few patients for clinical testing of its drug-device combination for MRI lung scans will soon begin at a third trial site.
They've so far enrolled 85.4% of the required number of patients in the lung transplant pathway and 62.5% for the lung resection pathway.
This is up from 80% and 50% in mid-May.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE